Chapter 8021

At the same time, Liu Qinghe's move can be regarded as a fierce fight for light for the Chinese medical community.

Most importantly, it also laid a good foundation for Zhang Xiaofan to win the next Nobel Prize in medicine.

As for Liu Qinghe, he only needs to explain at the international exchange seminar that all these remarks and research results are based on some theoretical formulas of Zhang Xiaofan.

There is no doubt that this will bring unprecedented sensational effects to the whole world medical community.

After hearing this, Zhang Xiaofan felt that he could not laugh or cry.

Unexpectedly, Liu Qinghe, such an old scholar, was still working hard for his Nobel Prize in medicine.

When Liu Qinghe talked to himself about the Nobel Prize for medicine last time, Zhang Xiaofan politely refused, indicating that he really didn't care about the fame and wealth of the secular world.

But later, seeing that Liu Qinghe was so interested in running for the next Nobel Prize for medicine, Zhang Xiaofan didn't take it too seriously.

At the same time, he didn't refuse Liu Qinghe's kindness to himself. Let Liu Qing and himself prepare for it.

After Liu Qinghe left Xuanji group, the research and development of new drugs, as well as the press conference, were postponed temporarily.

For some of the most core and key secrets of Xuanji Pharmaceutical Group, only Zhang Xiaofan can do it.

In particular, when designing the "silver bullet" anticancer drug, which is the foundation for the development of Xuanji Pharmaceutical Group, it is not as simple as it seems.

Because the key base drug for making "silver bullet" anticancer drugs can only be found in miaojiang and Baihua Valley, which is under the jurisdiction of Zhang Xiaofan.

In addition to the problem of the important raw materials of "silver bullet", the successful production of "silver bullet" anticancer drugs still needs to be repaired. The threshold of drug refining technology is at.

In the face of so many technical barriers of "silver bullets" and the monopoly of pharmaceutical raw materials, that is to say, Liu Qinghe has really decided to resign now even if he takes 10000 steps back.

Unless he takes away all the raw materials that can produce silver bullet anticancer drugs from baihuagu, miaojiang, and further grasps the medicine refining knowledge of the cultivation world.

So, Liu Qinghe just had a chance to develop the "silver bullet" anticancer drug.

If not, Liu Qinghe and the current overall development level of Chinese medicine alone would not be able to imitate the "silver bullet" anticancer drugs.

As for the products developed by Liu Qinghe, which are more responsible for occupying the mid-range pharmaceutical market than the ordinary specific drugs.

If competitive companies can get the prescriptions of these special effects through commercial spies, there is still a great probability that they can imitate and copy them.

However, as long as Xuanji Pharmaceutical Group has mastered the core technology, that is, silver bullet, it will be able to stand in an invincible position.

As for other Xuanji Pharmaceutical Group's new special drug product launch.

For such a large group as Xuanji Pharmaceutical Group, the role that large enterprises can play is nothing more than icing on the cake, which can further improve the group's product line.